Advanced search
Publication Cover
Acta Oncologica Volume 49, 2010 - Issue 1
Journal homepage
632
Views
4
CrossRef citations to date
0
Altmetric
LETTER TO THE EDITOR

Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®)

Henrik Kindmark Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, SwedenCorrespondence[email protected]
,
Eva Tiensuu Janson Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, SwedenCorrespondence[email protected]
,
Bengt Gustavsson Novartis, SwedenCorrespondence[email protected]
,
Camilla Eriksson Novartis, SwedenCorrespondence[email protected]
,
Gunnel Larsson Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, SwedenCorrespondence[email protected]
,
Dan Granberg Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, SwedenCorrespondence[email protected]
,
Gordana Kozlowacki Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, SwedenCorrespondence[email protected]
,
Britt Skogseid Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, SwedenCorrespondence[email protected]
,
Staffan Welin Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, SwedenCorrespondence[email protected]
,
Kjell Öberg Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, SwedenCorrespondence[email protected]
&
Barbro Eriksson Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, SwedenCorrespondence[email protected]
 show all
Pages 100-101 | Received 13 Mar 2009, Accepted 15 Mar 2009, Published online: 26 Jan 2010
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days
"Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®)." Acta Oncologica, 49(1), pp. 100–101

Acknowledgements

This study was supported by Novartis. The authors thank Åsa Forsberg, laboratory technician, for her excellent technical assistance.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.